Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 8/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26997900 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2XPNPEP1DPP4DPP8DPP9 | |
| SCHEMBL19432460 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2DPP4DPP8NPC1RAB9A | |
| SCHEMBL26724937 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2DPP4DPP8NPC1RAB9A | |
| SCHEMBL26213423 | 0.83 | NPC1 (0.44) | DPP4NPC1RAB9APOLBL3MBTL1 | |
| SCHEMBL22513826 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2NPC1RAB9APOLBL3MBTL1 | |
| SCHEMBL26207664 | 0.81 | NPC1 (0.36) | XPNPEP1DPP4DPP8DPP9DPP7 | |
| SCHEMBL9675542 | 0.80 | POLB (0.59) | SMN1; SMN2DPP4DPP8RAB9APOLB | |
| SCHEMBL7539826 | 0.80 | POLB (0.59) | SMN1; SMN2DPP4DPP8RAB9APOLB | |
| SCHEMBL7542669 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2XPNPEP1DPP4DPP8DPP9 | |
| SCHEMBL22296756 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SMN1; SMN2 2633/4885XPNPEP1 473/4885DPP4 332/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | SMN1; SMN2 2633/4885XPNPEP1 473/4885DPP4 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.